TRP channels as targets for therapeutic intervention in obesity: Focus on TRPV1 and TRPM5

Current Topics in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 247-257

  Palmer, R Kyle ^a   Lunn, Charles A ^a  

^a EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Drug targets; Obesity; TRP channels

Indexed keywords

CAPSAICIN; CAPSAICIN DERIVATIVE; CAPSIATE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LORCASERIN; PIPERINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN; VANILLOID RECEPTOR 1;

AGEUSIA; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; ENERGY CONSUMPTION; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERMOREGULATION;

ANIMALS; ANTI-OBESITY AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; OBESITY; TRPV CATION CHANNELS;

EID: 84876698097     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990089     Document Type: Article

References (156)

1. Centers for Disease Control and Prevention http://www.cdc.gov/obesity/data/adult.html. Last accessed October 10, 2012.
2. Flegal, K.M.; Carroll, M.D.; Ogden, C.L.; Curtin, L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA., 2010, 303(3), 235-241.
3. Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; Lamb, M.M.; Flegal, K.M. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA., 2010, 303(3), 242-249.
4. Barton, M. Childhood obesity: a life-long health risk. Acta. Pharmacol. Sin., 2012, 33(2), 189-193.
5. Lloyd, L.J.; Langley-Evans, S.C.; McMullen, S. Childhood obesity and risk of the adult metabolic syndrome: a systematic review. Int. J. Obes. (Lond)., 2012, 36(1), 1-11.
6. Pelone, F.; Specchia, M.L.; Veneziano, M.A.; Capizzi, S.; Bucci, S.; Mancuso, A.; Ricciardi, W.; de Belvis, A.G. Economic impact of childhood obesity on health systems: a systematic review. Obes. Rev., 2012, 13(5), 431-440.
7. Russell, G.V.; Pierce, C.W.; Nunley, L. Financial implications of obesity. Orthop. Clin. North. Am., 2011, 42(1), 123-127, vii.
8. Ara, R.; Blake, L.; Gray, L.; Hernandez, M.; Crowther, M.; Dunkley, A.; Warren, F.; Jackson, R.; Rees, A.; Stevenson, M.; Abrams, K.; Cooper, N.; Davies, M.; Khunti, K.; Sutton, A. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health. Technol. Assess., 2012, 16(5), iii-xiv, 1-195.
9. Neovius, M.; Narbro, K. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int. J. Obes. (Lond)., 2008, 32(12), 1752-1763.
10. Lenard, N.R.; Berthoud, H.R. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity. (Silver. Spring)., 2008, 16. Suppl. 3, S11-22.
11. Steenhuis, I.H.; Vermeer, W.M. Portion size: review and framework for interventions. Int. J. Behav. Nutr. Phys. Act., 2009, 6, 58.
12. Piernas, C.; Popkin, B.M. Increased portion sizes from energy-dense foods affect total energy intake at eating occasions in US children and adolescents: patterns and trends by age group and sociodemographic characteristics, 1977-2006. Am. J. Clin. Nutr., 2011, 94(5), 1324-1332.
13. Nielsen, S.J.; Siega-Riz, A.M.; Popkin, B.M. Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes. Res., 2002, 10(5), 370-378.
14. Kirk, S.F.; Penney, T.L.; McHugh, T.L. Characterizing the obesogenic environment: the state of the evidence with directions for future research. Obes. Rev., 2010, 11(2), 109-117.
15. Prentice-Dunn, H.; Prentice-Dunn, S. Physical activity, sedentary behavior, and childhood obesity: a review of cross-sectional studies. Psychol. Health. Med., 2012, 17(3), 255-273.
16. Must, A.; Tybor, D.J. Physical activity and sedentary behavior: a review of longitudinal studies of weight and adiposity in youth. Int. J. Obes. (Lond)., 2005, 29. Suppl. 2, S84-96.
17. Westerterp, K.R.; Speakman, J.R. Physical activity energy expenditure has not declined since the 1980s and matches energy expenditures of wild mammals. Int. J. Obes. (Lond)., 2008, 32(8), 1256-1263.
18. Fowler, S.P.; Williams, K.; Resendez, R.G.; Hunt, K.J.; Hazuda, H.P.; Stern, M.P. Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain. Obesity. (Silver. Spring)., 2008, 16(8), 1894-1900.
19. Swithers, S.E.; Davidson, T.L. A role for sweet taste: calorie predictive relations in energy regulation by rats. Behav. Neurosci., 2008, 122(1), 161-173.
20. Swithers, S.E.; Baker, C.R.; Davidson, T.L. General and persistent effects of high-intensity sweeteners on body weight gain and caloric compensation in rats. Behav. Neurosci., 2009, 123(4), 772-780.
21. Swithers, S.E.; Martin, A.A.; Davidson, T.L. High-intensity sweeteners and energy balance. Physiol. Behav., 2010, 100(1), 55-62.
22. Mattes, R. Effects of aspartame and sucrose on hunger and energy intake in humans. Physiol. Behav., 1990, 47(6), 1037-1044.
23. Cook, C.M.; Schoeller, D.A. Physical activity and weight control: conflicting findings. Curr. Opin. Clin. Nutr. Metab. Care., 2011, 14(5), 419-424.
24. Heal, D.J.; Gosden, J.; Smith, S.L. A review of late-stage CNS drug candidates for the treatment of obesity. Int. J. Obes. (Lond)., 2013. 37(1), 107-117.
25. Halford, J.C.; Boyland, E.J.; Lawton, C.L.; Blundell, J.E.; Harrold, J.A. Serotonergic anti-obesity agents: past experience and future prospects. Drugs., 2011, 71(17), 2247-2255.
26. Engeli, S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb. Exp. Pharmacol., 2012(209), 357-381.
27. Nelson, D.L.; Gehlert, D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine., 2006, 29(1), 49-60.
28. Derosa, G.; Maffioli, P. Anti-obesity drugs: a review about their effects and their safety. Expert. Opin. Drug. Saf., 2012, 11(3), 459-471.
29. Field, B.C.; Chaudhri, O.B.; Bloom, S.R. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol., 2009, 68(6), 830-843.
30. Zhu, Z.; Luo, Z.; Ma, S.; Liu, D. TRP channels and their implications in metabolic diseases. Pflugers. Arch., 2011, 461(2), 211-223.
31. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature., 1997, 389(6653), 816-824.
32. Nieto-Posadas, A.; Jara-Oseguera, A.; Rosenbaum, T. TRP channel gating physiology. Curr. Top. Med. Chem., 2011, 11(17), 2131-2150.
33. Ross, R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol., 2003, 140(5), 790-801.
34. Nagy, I.; Santha, P.; Jancso, G.; Urban, L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur. J. Pharmacol., 2004, 500(1-3), 351-369.
35. Gunthorpe, M.J.; Szallasi, A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des., 2008, 14(1), 32-41.
36. Jara-Oseguera, A.; Simon, S.A.; Rosenbaum, T. TRPV1: on the road to pain relief. Curr. Mol. Pharmacol., 2008, 1(3), 255-269.
37. Holzer, P. The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor. Br. J. Pharmacol., 2008, 155(8), 1145-1162.
38. Szallasi, A.; Cortright, D.N.; Blum, C.A.; Eid, S.R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug. Discov., 2007, 6(5), 357-372.
39. Xia, R.; Dekermendjian, K.; Lullau, E.; Dekker, N. TRPV1: a therapy target that attracts the pharmaceutical interests. Adv. Exp. Med. Biol., 2011, 704, 637-665.
40. Voight, E.A.; Kort, M.E. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert. Opin. Ther. Pat., 2010, 20(9), 1107-1122.
41. Zhang, L.L.; Yan Liu, D.; Ma, L.Q.; Luo, Z.D.; Cao, T.B.; Zhong, J.; Yan, Z.C.; Wang, L.J.; Zhao, Z.G.; Zhu, S.J.; Schrader, M.; Thilo, F.; Zhu, Z.M.; Tepel, M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ. Res., 2007, 100(7), 1063-1070.
42. Miller, C.W.; Casimir, D.A.; Ntambi, J.M. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology., 1996, 137(12), 5641-5650.
43. Park, U.H.; Jeong, H.S.; Jo, E.Y.; Park, T.; Yoon, S.K.; Kim, E.J.; Jeong, J.C.; Um, S.J. Piperine, a component of black pepper, inhibits adipogenesis by antagonizing PPARgamma activity in 3T3-L1 cells. J. Agric. Food. Chem., 2012, 60(15), 3853-3860.
44. Motter, A.L.; Ahern, G.P. TRPV1-null mice are protected from diet-induced obesity. FEBS. Lett., 2008, 582(15), 2257-2262.
45. Garami, A.; Pakai, E.; Oliveira, D.L.; Steiner, A.A.; Wanner, S.P.; Almeida, M.C.; Lesnikov, V.A.; Gavva, N.R.; Romanovsky, A.A. Thermoregulatory phenotype of the Trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesis. J. Neurosci., 2011, 31(5), 1721-1733.
46. Wanner, S.P.; Garami, A.; Romanovsky, A.A. Hyperactive when young, hypoactive and overweight when aged: connecting the dots in the story about locomotor activity, body mass, and aging in Trpv1 knockout mice. Aging. (Albany. NY)., 2011, 3(4), 450-454.
47. Enerback, S. Human brown adipose tissue. Cell. Metab., 2010, 11(4), 248-252.
48. Kozak, L.P.; Koza, R.A.; Anunciado-Koza, R. Brown fat thermogenesis and body weight regulation in mice: relevance to humans. Int. J. Obes. (Lond)., 2010, 34. Suppl. 1, S23-27.
49. Cui, J.; Himms-Hagen, J. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. Am. J. Physiol., 1992, 262(4 Pt 2), R568-573.
50. Melnyk, A.; Himms-Hagen, J. Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment. Obes. Res., 1995, 3(4), 337-344.
51. Osaka, T.; Kobayashi, A.; Namba, Y.; Ezaki, O.; Inoue, S.; Kimura, S.; Lee, T.H. Temperature-and capsaicin-sensitive nerve fibers in brown adipose tissue attenuate thermogenesis in the rat. Pflugers. Arch., 1998, 437(1), 36-42.
52. De Matteis, R.; Ricquier, D.; Cinti, S. TH-, NPY-, SP-, and CGRP-immunoreactive nerves in interscapular brown adipose tissue of adult rats acclimated at different temperatures: an immunohistochemical study. J. Neurocytol., 1998, 27(12), 877-886.
53. Petho, G.; Izydorczyk, I.; Reeh, P.W. Effects of TRPV1 receptor antagonists on stimulated iCGRP release from isolated skin of rats and TRPV1 mutant mice. Pain., 2004, 109(3), 284-290.
54. Walker, C.S.; Li, X.; Whiting, L.; Glyn-Jones, S.; Zhang, S.; Hickey, A.J.; Sewell, M.A.; Ruggiero, K.; Phillips, A.R.; Kraegen, E.W.; Hay, D.L.; Cooper, G.J.; Loomes, K.M. Mice lacking the neuropeptide alpha-calcitonin gene-related peptide are protected against diet-induced obesity. Endocrinology., 2010, 151(9), 4257-4269.
55. Gram, D.X.; Hansen, A.J.; Wilken, M.; Elm, T.; Svendsen, O.; Carr, R.D.; Ahren, B.; Brand, C.L. Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur. J. Endocrinol., 2005, 153(6), 963-969.
56. Hsu, C.L.; Yen, G.C. Effects of capsaicin on induction of apoptosis and inhibition of adipogenesis in 3T3-L1 cells. J. Agric. Food. Chem., 2007, 55(5), 1730-1736.
57. Richard, D.; Picard, F. Brown fat biology and thermogenesis. Front. Biosci., 2011, 16, 1233-1260.
58. Masuda, Y.; Haramizu, S.; Oki, K.; Ohnuki, K.; Watanabe, T.; Yazawa, S.; Kawada, T.; Hashizume, S.; Fushiki, T. Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. J. Appl. Physiol., 2003, 95(6), 2408-2415.
59. Puigserver, P.; Spiegelman, B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev., 2003, 24(1), 78-90.
60. Luo, Z.; Ma, L.; Zhao, Z.; He, H.; Yang, D.; Feng, X.; Ma, S.; Chen, X.; Zhu, T.; Cao, T.; Liu, D.; Nilius, B.; Huang, Y.; Yan, Z.; Zhu, Z. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1alpha upregulation in mice. Cell. Res., 2012, 22(3), 551-564.
61. Wenz, T.; Rossi, S.G.; Rotundo, R.L.; Spiegelman, B.M.; Moraes, C.T. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(48), 20405-20410.
62. Bostrom, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Bostrom, E.A.; Choi, J.H.; Long, J.Z.; Kajimura, S.; Zingaretti, M.C.; Vind, B.F.; Tu, H.; Cinti, S.; Hojlund, K.; Gygi, S.P.; Spiegelman, B.M. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature., 2012, 481(7382), 463-468.
63. Watanabe, T.; Kawada, T.; Iwai, K. Effect of capsaicin pretreatment on capsaicin-induced catecholamine secretion from the adrenal medulla in rats. Proc. Soc. Exp. Biol. Med., 1988, 187(3), 370-374.
64. Watanabe, T.; Kawada, T.; Kato, T.; Harada, T.; Iwai, K. Effects of capsaicin analogs on adrenal catecholamine secretion in rats. Life. Sci., 1994, 54(5), 369-374.
65. Kawada, T.; Watanabe, T.; Takaishi, T.; Tanaka, T.; Iwai, K. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. Proc. Soc. Exp. Biol. Med., 1986, 183(2), 250-256.
66. Kawada, T.; Suzuki, T.; Takahashi, M.; Iwai, K. Gastrointestinal absorption and metabolism of capsaicin and dihydrocapsaicin in rats. Toxicol. Appl. Pharmacol., 1984, 72(3), 449-456.
67. Donnerer, J.; Amann, R.; Schuligoi, R.; Lembeck, F. Absorption and metabolism of capsaicinoids following intragastric administration in rats. Naunyn. Schmiedebergs. Arch. Pharmacol., 1990, 342(3), 357-361.
68. Kawabata, F.; Inoue, N.; Masamoto, Y.; Matsumura, S.; Kimura, W.; Kadowaki, M.; Higashi, T.; Tominaga, M.; Inoue, K.; Fushiki, T. Non-pungent capsaicin analogs (capsinoids) increase metabolic rate and enhance thermogenesis via gastrointestinal TRPV1 in mice. Biosci. Biotechnol. Biochem., 2009, 73(12), 2690-2697.
69. Inoue, N.; Matsunaga, Y.; Satoh, H.; Takahashi, M. Enhanced energy expenditure and fat oxidation in humans with high BMI scores by the ingestion of novel and non-pungent capsaicin analogues (capsinoids). Biosci. Biotechnol. Biochem., 2007, 71(2), 380-389.
70. Josse, A.R.; Sherriffs, S.S.; Holwerda, A.M.; Andrews, R.; Staples, A.W.; Phillips, S.M. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise. Nutr. Metab. (Lond)., 2010, 7, 65.
71. Snitker, S.; Fujishima, Y.; Shen, H.; Ott, S.; Pi-Sunyer, X.; Furuhata, Y.; Sato, H.; Takahashi, M. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. Am. J. Clin. Nutr., 2009, 89(1), 45-50.
72. Yoneshiro, T.; Aita, S.; Kawai, Y.; Iwanaga, T.; Saito, M. Nonpungent capsaicin analogs (capsinoids) increase energy expenditure through the activation of brown adipose tissue in humans. Am. J. Clin. Nutr., 2012, 95(4), 845-850.
73. Galgani, J.E.; Ryan, D.H.; Ravussin, E. Effect of capsinoids on energy metabolism in human subjects. Br. J. Nutr., 2010, 103(1), 38-42.
74. Galgani, J.E.; Ravussin, E. Effect of dihydrocapsiate on resting metabolic rate in humans. Am. J. Clin. Nutr., 2010, 92(5), 1089-1093.
75. Ludy, M.J.; Moore, G.E.; Mattes, R.D. The effects of capsaicin and capsiate on energy balance: critical review and meta-analyses of studies in humans. Chem. Senses., 2012, 37(2), 103-121.
76. Xing, J.; Chen, J.D. Alterations of gastrointestinal motility in obesity. Obes. Res., 2004, 12(11), 1723-1732.
77. Horner, K.M.; Byrne, N.M.; Cleghorn, G.J.; Naslund, E.; King, N.A. The effects of weight loss strategies on gastric emptying and appetite control. Obes. Rev., 2011, 12(11), 935-951.
78. Debreceni, A.; Abdel-Salam, O.M.; Figler, M.; Juricskay, I.; Szolcsanyi, J.; Mozsik, G. Capsaicin increases gastric emptying rate in healthy human subjects measured by 13C-labeled octanoic acid breath test. J. Physiol. Paris., 1999, 93(5), 455-460.
79. Gonzalez, R.; Dunkel, R.; Koletzko, B.; Schusdziarra, V.; Allescher, H.D. Effect of capsaicin-containing red pepper sauce suspension on upper gastrointestinal motility in healthy volunteers. Dig. Dis. Sci., 1998, 43(6), 1165-1171.
80. de Man, J.G.; Boeckx, S.; Anguille, S.; de Winter, B.Y.; de Schepper, H.U.; Herman, A.G.; Pelckmans, P.A. Functional study on TRPV1-mediated signalling in the mouse small intestine: involvement of tachykinin receptors. Neurogastroenterol. Motil., 2008, 20(5), 546-556.
81. Prawitt, D.; Monteilh-Zoller, M.K.; Brixel, L.; Spangenberg, C.; Zabel, B.; Fleig, A.; Penner, R. TRPM5 is a transient Ca2+-activated cation channel responding to rapid changes in [Ca2+]i. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(25), 15166-15171.
82. Perez, C.A.; Huang, L.; Rong, M.; Kozak, J.A.; Preuss, A.K.; Zhang, H.; Max, M.; Margolskee, R.F. A transient receptor potential channel expressed in taste receptor cells. Nat. Neurosci., 2002, 5(11), 1169-1176.
83. Huang, Y.A.; Roper, S.D. Intracellular Ca(2+) and TRPM5-mediated membrane depolarization produce ATP secretion from taste receptor cells. J. Physiol., 2010, 588(Pt 13), 2343-2350.
84. Jang, H.J.; Kokrashvili, Z.; Theodorakis, M.J.; Carlson, O.D.; Kim, B.J.; Zhou, J.; Kim, H.H.; Xu, X.; Chan, S.L.; Juhaszova, M.; Bernier, M.; Mosinger, B.; Margolskee, R.F.; Egan, J.M. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(38), 15069-15074.
85. Lin, W.; Ezekwe, E.A. Jr.; Zhao, Z.; Liman, E.R.; Restrepo, D. TRPM5-expressing microvillous cells in the main olfactory epithelium. BMC. Neurosci., 2008, 9, 114.
86. Thompson, J.A.; Salcedo, E.; Restrepo, D.; Finger, T.E. Second-order input to the medial amygdala from olfactory sensory neurons expressing the transduction channel TRPM5. J. Comp. Neurol., 2012, 520(8), 1819-1830.
87. Kokrashvili, Z.; Rodriguez, D.; Yevshayeva, V.; Zhou, H.; Margolskee, R.F.; Mosinger, B. Release of endogenous opioids from duodenal enteroendocrine cells requires Trpm5. Gastroenterology., 2009, 137(2), 598-606, 606 e591-592.
88. Bezencon, C.; Furholz, A.; Raymond, F.; Mansourian, R.; Metairon, S.; Le Coutre, J.; Damak, S. Murine intestinal cells expressing Trpm5 are mostly brush cells and express markers of neuronal and inflammatory cells. J. Comp. Neurol., 2008, 509(5), 514-525.
89. Brixel, L.R.; Monteilh-Zoller, M.K.; Ingenbrandt, C.S.; Fleig, A.; Penner, R.; Enklaar, T.; Zabel, B.U.; Prawitt, D. TRPM5 regulates glucose-stimulated insulin secretion. Pflugers. Arch., 2010, 460(1), 69-76.
90. Colsoul, B.; Schraenen, A.; Lemaire, K.; Quintens, R.; Van Lommel, L.; Segal, A.; Owsianik, G.; Talavera, K.; Voets, T.; Margolskee, R.F.; Kokrashvili, Z.; Gilon, P.; Nilius, B.; Schuit, F.C.; Vennekens, R. Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5-/-mice. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(11), 5208-5213.
91. Palmer, R.K. The pharmacology and signaling of bitter, sweet, and umami taste sensing. Mol. Interv., 2007, 7(2), 87-98.
92. Zhang, Y.; Hoon, M.A.; Chandrashekar, J.; Mueller, K.L.; Cook, B.; Wu, D.; Zuker, C.S.; Ryba, N.J. Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways. Cell., 2003, 112(3), 293-301.
93. Damak, S.; Rong, M.; Yasumatsu, K.; Kokrashvili, Z.; Perez, C.A.; Shigemura, N.; Yoshida, R.; Mosinger, B. Jr.; Glendinning, J.I.; Ninomiya, Y.; Margolskee, R.F. Trpm5 null mice respond to bitter, sweet, and umami compounds. Chem. Senses., 2006, 31(3), 253-264.
94. Mattes, R.D. Accumulating evidence supports a taste component for free fatty acids in humans. Physiol. Behav., 2011, 104(4), 624-631.
95. Shah, B.P.; Liu, P.; Yu, T.; Hansen, D.R.; Gilbertson, T.A. TRPM5 is critical for linoleic acid-induced CCK secretion from the enteroendocrine cell line, STC-1. Am. J. Physiol. Cell. Physiol., 2012, 302(1), C210-219.
96. Bryant, R.W. Atwal, K.S. Bakaj, I. Buber, T. Carlucci, S. Cerne, R. Cortés, R. Devantier, H.R., Hendrix, C.J. Lee, S.P., Palmer, R.K. Wilson, C. Yang, Q. and Salemme, F.R. 2008, Development of transient receptor potential melanostatin 5 modulators for sweetness enhancement, D.K. Weerasinghe and G.E. DuBois (Ed.), American Chemical Society, 979, 386.
97. Li X. and Servant, G. 2008, Functional characterization of the human sweet receptor: high-throughput screening assay development and structural function relation, D.K. Weerasinghe and G.E. DuBois (Ed.), American Chemical Society, 979, 368.
98. Servant, G.; Tachdjian, C.; Tang, X.Q.; Werner, S.; Zhang, F.; Li, X.; Kamdar, P.; Petrovic, G.; Ditschun, T.; Java, A.; Brust, P.; Brune, N.; DuBois, G.E.; Zoller, M.; Karanewsky, D.S. Positive allosteric modulators of the human sweet taste receptor enhance sweet taste. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(10), 4746-4751.
99. Sprous, D.; Palmer, K.R. The T1R2/T1R3 sweet receptor and TRPM5 ion channel taste targets with therapeutic potential. Prog. Mol. Biol. Transl. Sci., 2010, 91, 151-208.
100. Fonfria, E.; Murdock, P.R.; Cusdin, F.S.; Benham, C.D.; Kelsell, R.E.; McNulty, S. Tissue distribution profiles of the human TRPM cation channel family. J. Recept. Signal. Transduct. Res., 2006, 26(3), 159-178.
101. Kyriazis, G.A.; Soundarapandian, M.M.; Tyrberg, B. Sweet taste receptor signaling in beta cells mediates fructose-induced potentiation of glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(8), E524-532.
102. Reimann, F.; Habib, A.M.; Tolhurst, G.; Parker, H.E.; Rogers, G.J.; Gribble, F.M. Glucose sensing in L cells: a primary cell study. Cell. Metab., 2008, 8(6), 532-539.
103. Donnelly, D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br. J. Pharmacol., 2012, 166(1), 27-41.
104. Naslund, E.; Bogefors, J.; Skogar, S.; Gryback, P.; Jacobsson, H.; Holst, J.J.; Hellstrom, P.M. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J. Physiol., 1999, 277(3 Pt 2), R910-916.
105. Tzefos, M.; Harris, K.; Brackett, A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann. Pharmacother., 2012, 46(1), 68-78.
106. Asarian, L.; Corp, E.S.; Hrupka, B.; Geary, N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol. Behav., 1998, 64(3), 367-372.
107. Chelikani, P.K.; Haver, A.C.; Reidelberger, R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288(6), R1695-1706.
108. Flint, A.; Raben, A.; Astrup, A.; Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest., 1998, 101(3), 515-520.
109. Naslund, E.; Barkeling, B.; King, N.; Gutniak, M.; Blundell, J.E.; Holst, J.J.; Rossner, S.; Hellstrom, P.M. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord., 1999, 23(3), 304-311.
110. Wynne, K.; Bloom, S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat. Clin. Pract. Endocrinol. Metab., 2006, 2(11), 612-620.
111. Gerspach, A.C.; Steinert, R.E.; Schonenberger, L.; Graber-Maier, A.; Beglinger, C. The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. Am. J. Physiol. Endocrinol. Metab., 2011, 301(2), E317-325.
112. Kaske, S.; Krasteva, G.; Konig, P.; Kummer, W.; Hofmann, T.; Gudermann, T.; Chubanov, V. TRPM5, a taste-signaling transient receptor potential ion-channel, is a ubiquitous signaling component in chemosensory cells. BMC. Neurosci., 2007, 8, 49.
113. Hass, N.; Schwarzenbacher, K.; Breer, H. T1R3 is expressed in brush cells and ghrelin-producing cells of murine stomach. Cell. Tissue. Res., 2010, 339(3), 493-504.
114. Bezencon, C.; Le Coutre, J.; Damak, S. Taste-signaling proteins are coexpressed in solitary intestinal epithelial cells. Chem. Senses., 2007, 32(1), 41-49.
115. Dirksen, C.; Jorgensen, N.B.; Bojsen-Moller, K.N.; Jacobsen, S.H.; Hansen, D.L.; Worm, D.; Holst, J.J.; Madsbad, S. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia., 2012, 55(7), 1890-1901.
116. Burge, J.C.; Schaumburg, J.Z.; Choban, P.S.; DiSilvestro, R.A.; Flancbaum, L. Changes in patients' taste acuity after Roux-en-Y gastric bypass for clinically severe obesity. J. Am. Diet. Assoc., 1995, 95(6), 666-670.
117. Le Roux, C.W.; Bueter, M.; Theis, N.; Werling, M.; Ashrafian, H.; Lowenstein, C.; Athanasiou, T.; Bloom, S.R.; Spector, A.C.; Olbers, T.; Lutz, T.A. Gastric bypass reduces fat intake and preference. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 301(4), R1057-1066.
118. Glendinning, J.I.; Gillman, J.; Zamer, H.; Margolskee, R.F.; Sclafani, A. The role of T1r3 and Trpm5 in carbohydrate-induced obesity in mice. Physiol. Behav., 2012, 107(1), 50-58.
119. Eddy, M.C.; Eschle, B.K.; Peterson, D.; Lauras, N.; Margolskee, R.F.; Delay, E.R. A conditioned aversion study of sucrose and SC45647 taste in TRPM5 knockout mice. Chem. Senses., 2012, 37(5), 391-401.
120. Sclafani, A.; Zukerman, S.; Glendinning, J.I.; Margolskee, R.F. Fat and carbohydrate preferences in mice: the contribution of alpha-gustducin and Trpm5 taste-signaling proteins. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 293(4), R1504-1513.
121. Zhang, F.; Klebansky, B.; Fine, R.M.; Liu, H.; Xu, H.; Servant, G.; Zoller, M.; Tachdjian, C.; Li, X. Molecular mechanism of the sweet taste enhancers. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(10), 4752-4757.
122. Dramane, G.; Akpona, S.; Simonin, A.M.; Besnard, P.; Khan, N.A. Cell signaling mechanisms of gustatory perception of lipids: can the taste cells be the target of anti-obesity agents? Curr. Med. Chem., 2011, 18(22), 3417-3422.
123. Malik, V.S.; Schulze, M.B.; Hu, F.B. Intake of sugar-sweetened beverages and weight gain: a systematic review. Am. J. Clin. Nutr., 2006, 84(2), 274-288.
124. Kelley, A.E.; Bakshi, V.P.; Haber, S.N.; Steininger, T.L.; Will, M.J.; Zhang, M. Opioid modulation of taste hedonics within the ventral striatum. Physiol. Behav., 2002, 76(3), 365-377.
125. Hoebel, B.G.; Avena, N.M.; Bocarsly, M.E.; Rada, P. Natural addiction: a behavioral and circuit model based on sugar addiction in rats. J. Addict. Med., 2009, 3(1), 33-41.
126. Geiger, B.M.; Haburcak, M.; Avena, N.M.; Moyer, M.C.; Hoebel, B.G.; Pothos, E.N. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience., 2009, 159(4), 1193-1199.
127. Kenny, P.J. Reward mechanisms in obesity: new insights and future directions. Neuron., 2011, 69(4), 664-679.
128. Liu, P.; Shah, B.P.; Croasdell, S.; Gilbertson, T.A. Transient receptor potential channel type M5 is essential for fat taste. J. Neurosci., 2011, 31(23), 8634-8642.
129. Heckmann, J.G.; Stossel, C.; Lang, C.J.; Neundorfer, B.; Tomandl, B.; Hummel, T. Taste disorders in acute stroke: a prospective observational study on taste disorders in 102 stroke patients. Stroke., 2005, 36(8), 1690-1694.
130. Naik, B.S.; Shetty, N.; Maben, E.V. Drug-induced taste disorders. Eur. J. Intern. Med., 2010, 21(3), 240-243.
131. Nelson, G.M. Biology of taste buds and the clinical problem of taste loss. Anat. Rec., 1998, 253(3), 70-78.
132. Schiffman, S.S.; Graham, B.G. Taste and smell perception affect appetite and immunity in the elderly. Eur. J. Clin. Nutr., 2000, 54. Suppl. 3, S54-63.
133. Cave, A.J.; Cox, D.W.; Vicaruddin, O. Loss of taste with clopidogrel. Can. Fam. Physician., 2008, 54(2), 195-196.
134. Finsterer, J.; Stollberger, C.; Kopsa, W. Weight reduction due to stroke-induced dysgeusia. Eur. Neurol., 2004, 51(1), 47-49.
135. Woschnagg, H.; Stollberger, C.; Finsterer, J. Loss of taste is loss of weight. Lancet., 2002, 359(9309), 891.
136. Liedtke, W.B. In: TRPV. Channels'. Function. in. Sensory. Transduction. and. Cellular. Signaling. Cascades, Liedtke, W.B.; Heller, S.; Ed. CRC Press Boca Raton (FL), 2007, Chapter 22.
137. Guler, A.D.; Lee, H.; Iida, T.; Shimizu, I.; Tominaga, M.; Caterina, M. Heat-evoked activation of the ion channel, TRPV4. J. Neurosci., 2002, 22(15), 6408-6414.
138. Watanabe, H.; Vriens, J.; Prenen, J.; Droogmans, G.; Voets, T.; Nilius, B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature., 2003, 424(6947), 434-438.
139. Everaerts, W.; Nilius, B.; Owsianik, G. The vanilloid transient receptor potential channel TRPV4: from structure to disease. Prog. Biophys. Mol. Biol., 2010, 103(1), 2-17.
140. Kusudo, T.; Wang, Z.; Mizuno, A.; Suzuki, M.; Yamashita, H. TRPV4 deficiency increases skeletal muscle metabolic capacity and resistance against diet-induced obesity. J. Appl. Physiol., 2012, 112(7), 1223-1232.
141. Ye, L.; Kleiner, S.; Wu, J.; Sah, R.; Gupta, R.K.; Banks, A.S.; Cohen, P.; Khandekar, M.J.; Bostrom, P.; Mepani, R.J.; Laznik, D.; Kamenecka, T.M.; Song, X.; Liedtke, W.; Mootha, V.K.; Puigserver, P.; Griffin, P.R.; Clapham, D.E.; Spiegelman, B.M. TRPV4 Is a Regulator of Adipose Oxidative Metabolism, Inflammation, and Energy Homeostasis. Cell., 2012, 151(1), 96-110.
142. Phan, M.N.; Leddy, H.A.; Votta, B.J.; Kumar, S.; Levy, D.S.; Lipshutz, D.B.; Lee, S.H.; Liedtke, W.; Guilak, F. Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. Arthritis. Rheum., 2009, 60(10), 3028-3037.
143. Iwasaki, Y.; Tanabe, M.; Kobata, K.; Watanabe, T. TRPA1 agonists--allyl isothiocyanate and cinnamaldehyde--induce adrenaline secretion. Biosci. Biotechnol. Biochem., 2008, 72(10), 2608-2614.
144. Masamoto, Y.; Kawabata, F.; Fushiki, T. Intragastric administration of TRPV1, TRPV3, TRPM8, and TRPA1 agonists modulates autonomic thermoregulation in different manners in mice. Biosci. Biotechnol. Biochem., 2009, 73(5), 1021-1027.
145. Tamura, Y.; Iwasaki, Y.; Narukawa, M.; Watanabe, T. Ingestion of Cinnamaldehyde, a TRPA1 Agonist, Reduces Visceral Fats in Mice Fed a High-Fat and High-Sucrose Diet. J. Nutr. Sci. Vitaminol. (Tokyo)., 2012, 58(1), 9-13.
146. Penuelas, A.; Tashima, K.; Tsuchiya, S.; Matsumoto, K.; Nakamura, T.; Horie, S.; Yano, S. Contractile effect of TRPA1 receptor agonists in the isolated mouse intestine. Eur. J. Pharmacol., 2007, 576(1-3), 143-150.
147. Doihara, H.; Nozawa, K.; Kawabata-Shoda, E.; Kojima, R.; Yokoyama, T.; Ito, H. TRPA1 agonists delay gastric emptying in rats through serotonergic pathways. Naunyn. Schmiedebergs. Arch. Pharmacol., 2009, 380(4), 353-357.
148. Doihara, H.; Nozawa, K.; Kawabata-Shoda, E.; Kojima, R.; Yokoyama, T.; Ito, H. Molecular cloning and characterization of dog TRPA1 and AITC stimulate the gastrointestinal motility through TRPA1 in conscious dogs. Eur. J. Pharmacol., 2009, 617(1-3), 124-129.
149. Nozawa, K.; Kawabata-Shoda, E.; Doihara, H.; Kojima, R.; Okada, H.; Mochizuki, S.; Sano, Y.; Inamura, K.; Matsushime, H.; Koizumi, T.; Yokoyama, T.; Ito, H. TRPA1 regulates gastrointestinal motility through serotonin release from enterochromaffin cells. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(9), 3408-3413.
150. Tsvilovskyy, V.V.; Zholos, A.V.; Aberle, T.; Philipp, S.E.; Dietrich, A.; Zhu, M.X.; Birnbaumer, L.; Freichel, M.; Flockerzi, V. Deletion of TRPC4 and TRPC6 in mice impairs smooth muscle contraction and intestinal motility in. vivo. Gastroenterology., 2009, 137(4), 1415-1424.
151. Liu, S.; Qu, M.H.; Ren, W.; Hu, H.Z.; Gao, N.; Wang, G.D.; Wang, X.Y.; Fei, G.; Zuo, F.; Xia, Y.; Wood, J.D. Differential expression of canonical (classical) transient receptor potential channels in guinea pig enteric nervous system. J. Comp. Neurol., 2008, 511(6), 847-862.
152. Torihashi, S.; Fujimoto, T.; Trost, C.; Nakayama, S. Calcium oscillation linked to pacemaking of interstitial cells of Cajal: requirement of calcium influx and localization of TRP4 in caveolae. J. Biol. Chem., 2002, 277(21), 19191-19197.
153. Walker, R.L.; Koh, S.D.; Sergeant, G.P.; Sanders, K.M.; Horowitz, B. TRPC4 currents have properties similar to the pacemaker current in interstitial cells of Cajal. Am. J. Physiol. Cell. Physiol., 2002, 283(6), C1637-1645.
154. Kito, Y. The functional role of intramuscular interstitial cells of Cajal in the stomach. J. Smooth. Muscle. Res., 2011, 47(2), 47-53.
155. Kim, B.J.; So, I.; Kim, K.W. The relationship of TRP channels to the pacemaker activity of interstitial cells of Cajal in the gastrointestinal tract. J. Smooth. Muscle. Res., 2006, 42(1), 1-7.
156. Strubing, C.; Krapivinsky, G.; Krapivinsky, L.; Clapham, D.E. Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J. Biol. Chem., 2003, 278(40), 39014-39019.